Management and outcome of breast cancer patients with ipsilateral supraclavicular lymph nodes involvement at presentation retrospective study

3^rd Global summit on Oncology and Cancer

May 06-07, 2019 Tokyo, Japan

Ola Osama Ahmed Hafez

Cairo University, Egypt

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Breast cancer is the most common type of cancer and the most common cause of cancer-related mortality among women worldwide. About 4% have had ipsilateral Supraclavicular Lymph Nodes involvement (SCLNs). In spite this very low incidence, a big conflict occur in TNM staging and management. The current study was a retro prospective observational descriptive study. We re¬viewed the files of breast cancer patients with synchronized with ipsilateral SCLNs involvement without distant metastasis that were seen in the follow up clinic in the period (Feb 2016-August 2016) at NEMROCK oncology Department, Kasr Al Ainy School of Medicine. Clinic pathological data was described for 34 patients as age (median 50.5 years), menopausal status (pre-menopause were 47.1%), family history (positive in 23.5%), site of tumor (UOQ 67.6 %), side (Rt 52.9 %), hormonal receptors (positive in 58.8%), initial T (T3 and T4 70.6%). Treatment applied NAC was given to 73.5% and the response was regressive in 44% of patients, 64.7 % underwent mastectomy while 14.7 % gone for conservation, 41.1 % received adjuvant hormonal treatment, post-treatment pathological T (3,4) was 35.3 %. Local recurrence occur in 14.7%, systemic relapse occur in17.6%. We don't comment on overall survival because of selection bias. Although the incidence of patients with breast cancer who present with ipsilateral SCLNs involvement without distant spread at time of diagnosis is low. It seems reasonable to consider this selective patient group as a loco regional and thereby a potentially curable disease and should be treated with a curative rather than palliative intent. Nevertheless, one should keep in mind that patients presenting with supraclavicular disease are at high risk for harboring distant metastatic disease, even when clinically detectable metastases are not evident. Patients should be offered a combined-modality approach, including systemic therapy, surgery and radiotherapy.

Biography :

E-mail: olahafez@live.com